I spent yesterday at the Farber’s Multiple Myeloma Patient Education Symposium. As usual, it was a fascinating, informative day, which incorporated the latest results from the recent ASH conference in Orlando. The mood in the MM research and clinical community is ebullient these days. It has been a banner year for MM advances. There have been 7 FDA approvals for novel MM therapies this year